Skip to content

Advertisement

  • Short report
  • Open Access

Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay

  • 1Email author,
  • 2,
  • 3,
  • 4,
  • 4,
  • 1,
  • 3,
  • 5 and
  • 1
Contributed equally
Breast Cancer Research201820:75

https://doi.org/10.1186/s13058-018-1005-z

Published: 11 July 2018

Abstract

The 2013 update of the American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) human epidermal growth factor receptor 2 (HER2) testing guidelines recommend using an alternative chromosome 17 probe assay to resolve HER2 results determined to be equivocal by immunohistochemistry (IHC) or fluorescence in-situ hybridization (FISH). However, it is unclear if cases considered HER2-positive (HER2+) by the alternative probe method are similar to those classified as HER2+ by traditional IHC and FISH criteria and benefit the same from HER2-targeted therapies. We studied the clinical and pathologic features of all 31 breast cancers classified as HER2+ by the alternative probe method at our institution since 2013 and determined their PAM50 intrinsic molecular subtypes. For comparison, we analyzed 19 consecutive cases that were classified as HER2+ by traditional FISH criteria during the same time period. Thirty (97%) cancers in the alternative probe cohort were estrogen receptor (ER)-positive (ER+), while only 9/19 (47%) of traditional HER2 controls were ER+ (p = 0.0002). Sufficient tissue for intrinsic subtype analysis was available for 20/31 cancers in the alternative probe cohort and 9/19 in the traditional HER2+ group. None (0%) of the 20 alternative probe-positive cases were of the HER2-enriched intrinsic subtype, while 8/9 (89%) of those HER2+ by traditional FISH criteria were HER2-enriched (p = 0.0001). These findings suggest that breast cancers classified as HER2+ only by the alternative probe method are biologically distinct from those classified as HER2+ by traditional criteria, and raises questions as to whether or not they derive the same benefit from HER2-targeted therapies.

Keywords

  • HER2-positive breast cancer
  • PAM50 intrinsic subtype
  • HER2 alternative probe
  • ASCO-CAP guidelines

Approximately 15% of breast cancers are classified as human epidermal growth factor receptor 2 (HER2)-positive (HER2+) [1]. HER2 positivity confers an aggressive phenotype and was associated with poor long-term outcomes [2] until the incorporation of HER2-targeted agents into treatment which resulted in a 50% reduction in recurrence and a 30% improvement in survival [3, 4].

The two most common methods for HER2 testing are immunohistochemistry (IHC) to assess protein overexpression and fluorescence in-situ hybridization (FISH) to assess gene amplification. Single-probe FISH enumerates HER2 copies per nucleus. Dual-probe FISH includes both an HER2 probe and a chromosome 17 centromere probe, providing an HER2/CEP17 ratio in addition to absolute HER2 copy number [5]. Intrinsic molecular subtype analysis using gene expression profiling is not used clinically, but may better represent the inherent biologic heterogeneity of breast cancer than conventional biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and HER2 [6, 7]. While all intrinsic molecular subtypes have been observed among clinically HER2+ breast cancers defined by traditional IHC/FISH criteria, the majority (67%) are classified as HER2-enriched, with ER-positive (ER+)/HER2+ cases being HER2-enriched 54% of the time [8]. In contrast, among clinically HER2-negative (HER2) cases, only ~ 7% are of the HER2-enriched subtype [9]. Recent data suggest that the HER2-enriched molecular subtype may be a better predictor of response to HER2-targeted therapy than IHC or FISH assessments [10].

The American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) updated their HER2 testing guidelines in 2013 [11]. It is now recommended that for HER2 equivocal cases (i.e., IHC 2+ or HER2 copies ≥ 4 and < 6 and HER2/CEP17 ratio < 2), FISH be performed using a probe for other genes on chromosome 17 to serve as the denominator to determine the HER2/chromosome 17 ratio. Genes such as retinoic acid receptor alpha (RARA), Smith-Magenis Syndrome (SMS), or tumor protein p53 (TP53) are located further away from HER2 than the centromere and are thus less likely to be co-amplified with HER2 than the centromere. Thus, an HER2/alternative chromosome 17 probe ratio of ≥ 2 may more accurately reflect HER2 gene amplification than the HER2/CEP17 ratio [12].

Using the alternative probe method has resulted in an increased number of breast cancers classified as HER2-positive [13]. However, whether or not these cancers have similar clinical and pathologic features or respond as well to HER2-targeted therapy as breast cancers defined as HER2-positive by traditional IHC/FISH criteria is unclear.

We identified all breast cancers at our institution since 2013 classified as HER2-positive only by the alternative probe method. We identified 31 such cases, and 20 of those had sufficient tissue for PAM50 intrinsic subtype analysis. As a comparison group, we selected 19 consecutive cases classified as HER2+ by traditional FISH criteria during the same period. We reviewed their clinical and pathologic features and determined intrinsic molecular subtype analysis using the PAM50 research-based assay as previously described [14] (Tables 1 and 2).
Table 1

Clinical and pathologic characteristics of breast cancer patients with positive HER2 alternative probe

Patient no.

Histology

Grade

ER/PR

HER2 IHCa

HER2 Copies

HER2/CEP17 ratio

HER2/P53 ratio

HER2 FISH repeated on a 2nd tumor specimen

Intrinsic subtype

TNM stage

Herceptin ± chemo given?

NAT, AT, MET

Herceptin ± chemo regimenb

If NAT, pathologic response?

Follow-up timec

Disease status

1

IDC

3

+/+

+ 2

4.15

1.1

2.2

Negative

Luminal A

pT1aN0

No

N/A

N/A

N/A

16 months

Remission

2

ILC

2

+/−

+ 2

4.47

1.5

2.9

Negative

Normal

cT2N1

No

NAT

ddAC-T

PR

42 months

Remission

3

IDC

3

+/+

+ 2

5.77

1.8

2.8

Not done

Luminal A

cT3N0

Yes

NAT

THP

CR

22 months

Remission

4d

IDC

3

+/+

+ 2

4.9

1.2

2.8

Not done

Luminal B

cT1cN1

Yes

NAT

ddAC-THP

PR

16 months

Remission

5

IDC

2

+/+

0–1+

4.67

1.5

2.1

Pos by alt probe

Luminal A

pT1aN0

Yes

AT

TH

N/A

24 months

Remission

6e

IDC

2

+/+

+ 3

4.51

1.3

2.6

Pos by alt probe

Luminal B

pT1bNx

Yes

AT

TCy-HP

N/A

15 months

Remission

7

IDLC

2

+/+

+ 2

4.88

1.5

3.0

Pos by conventional FISHf

Luminal A

pT2N2

Yes

AT

ddAC-THP

N/A

12 months

Remission

8

IDLC

3

+/+

+ 2

4.05

1.9

2.2

Not done

Luminal A

pT1cN1a

Yes

AT

TCy-H

N/A

35 months

Remission

9

IDC

3

+/−

+ 2

4.62

1.5

2.7

Negative

Luminal B

cT1cN1a

Yes

AT

TCH

N/A

33 months

Remission

10

IDC

2

+/+

+ 2

5.42

1.5

2.6

Not done

Luminal A

cT2N1a

Yes

AT

ddAC-THP

N/A

31 months

Remission

11

IDLC

3

+/+

+ 3

5.42

1.3

2.6

Not done

Luminal B

cT2N0

Yes

AT

ddAC-THP

N/A

18 months

Remission

12

IDLC

2

+/+

+ 2

4.45

1.5

3.3

Negative

Luminal A

pT1bN0

Yes

AT

TH

N/A

29 months

Remission

13

IDC

2

+/+

+ 2

4.12

1.2

2.1

Negative

Luminal A

cT2N1M1b

Yes

MET

capecitabine

N/A

19 months

Stable dz

14

IDC

1

+/−

+ 3

5.93

1.7

2.8

na

Luminal A

na

na

na

na

na

na

na

15

IDC

3

−/−

0–1+

5.56

1.2

2.3

Negative

NS

cT2N0

Yes

NAT

ddAC-THP as NAT, capecitabine as AT

PR

27 months

Remission

16

IDC

2

+/+

+ 3

5.83

1.6

3.2

Not done

NS

pT1bN0

Yes

AT

TH

N/A

40 months

Remission

17

IDC

2

+/+

0–1+

4.17

1.3

2.3

Not done

NS

pT1cN1mi

No

AT

TCy

N/A

26 months

Remission

18

IDLC

2

+/+

+ 2

4.72

1.2

3.3

Not done

NS

pT1bN0

Yes

AT

trastuzumab and endocrine tx

N/A

2 months

Remission

19

ILC

2

+/+

+ 2

4.37

1.6

2.7

Not done

NS

cTxNxM1b

Yes

MET

Various chemo + anti-HER2 tx

N/A

36 months

Died of disease

20

ILC

2

+/+

+ 2

4.62

1.5

2.3

na

NS

na

na

na

na

na

na

na

21

IDLC

1

+/+

+ 2

4.42

1.4

2.6

na

NS

na

na

na

na

na

na

na

22

IDC

3

+/+

+ 2

4.42

1.6

2.2

na

NS

pT2N2Mx

na

na

na

na

 

na

23

IDC

1

+/+

+ 2

4.45

1.6

2.1

na

NS

na

na

na

na

na

na

na

24

IDLC

3

+/+

0–1+

4.13

1.5

2.9

Not done

NS

pT1cN0

na

na

na

na

na

na

25

IDLC

3

+/+

+ 2

4.68

1.2

2.5

na

NS

na

na

na

na

na

na

na

26d

IDLC

2

+/+

0–1+

5.13

1.4

2.1

Not done

Luminal A

pT1cN0

No

N/A

N/A

N/A

9 months

Remission

27d

IDLC

2

+/+

+ 2

4.22

1.7

3.2

Positive by conventional FISHf

Luminal A

pT1bN0

Yes

AT

TH ×2 weeks, then T-DM1 ×3 doses

N/A

13 months

Remission

28

IDC

3

+/+

+ 2

5.17

1.9

2.2

Not done

Luminal A

pT1bN0

Yes

AT

TH

N/A

7 months

Remission

29

IDC

2

+/+

+ 2

4.79

1.4

2.5

Negative

Luminal A

pT2N1a

Yes

AT

ddAC-THP

N/A

6 months

Remission

30

IDC

2

+/+

+ 2

4.45

1.6

3.5

na

Luminal B

na

na

na

na

na

na

na

31

IDC

2

+/+

+ 3

5.07

1.3

2.6

na

Luminal A

na

na

na

na

na

na

na

aHER2 IHC: 0–1+ is negative, 2+ is equivocal, 3+ is positive

bAll patients who received trastuzumab-based treatment received trastuzumab (H) for 1 year unless otherwise specified

cFollow up time defined as time in months from date of initial breast biopsy to date of last clinical follow-up

dPatients with oncotype Dx score: patient 4 score 29, patient 26 score 12, patient 27 score 21

ePatient had post-mastectomy recurrence and had history of prior ALND; so current nodal status could not be assessed

fRepeat HER2 testing for patient 7 showed HER2 copies of 4.53 and HER2/CEP17 ratio of 2.0 and for patient 27 showed HER2 copies of 6.5 and HER2/CEP17 ratio of 2.3

AT adjuvant therapy, CR complete response, ddAC dose-dense adriamycin + cyclophosphamide, ER estrogen receptor, FISH fluorescence in-situ hybridization, H herceptin (trastuzumab), HER2 human epidermal growth factor receptor 2, IDC invasive ductal cancer, IDLC invasive cancer with ductal and lobular features, IHC immunohistochemistry, ILC invasive lobular cancer, MET therapy for metastatic disease, N/A not applicable, na not available, NAT neoadjuvant therapy, NS not sufficient for testing, P pertuzumab, PR partial response, PR progesterone receptor, T weekly paclitaxel ×12, TC taxotere (docetaxel) + carboplatin, TCy taxotere (docetaxel) + cyclophosphamide, TNM tumor node metastasis, Tx therapy

Table 2

Randomly selected consecutive HER2+ cases by traditional FISH criteria

Patient no.

Histology

Grade

ER/PR

HER2 IHCa

HER2 copies

HER2/CEP17 ratio

Intrinsic subtype

TNM stage

Herceptin ± chemo given?

NAT, AT, MET

Herceptin ± chemo regimenb

If NAT, pathologic response?

Follow-up timec

Disease status

1

IDC

3

+/+

+ 3

19.1

5.8

NS

pT1cN0

No; patient declined

N/A

N/A

N/A

9 months

Remission

2

IMPC

2

−/−

+ 3

17.6

4.8

NS

pT1bNx

No; not offered 2/2 age/comorbidities

N/A

N/A

N/A

4 months

Died of AAA rupture

3

IDC

3

+/+

+ 3

20.6

6.6

Luminal A

cT2N1M0

Yes

NAT & AT

NAT: T-DM1 + P on a trial, AT: THP

PR

25 months

Remission

4

IDC

3

+/+

+ 3

> 10

5.2

HER2-E

cT1cN0

Yes

NAT & AT

NAT: T-DM1 + P on a trial, then AT: docetaxel ×4 cycles + H ×1 year

CR

12 months

Remission

5

IDC

3

−/−

+ 3

> 20

1.0d

HER2-E

cT1cN0

Yes

NAT

THP

CR

18 months

Remission

6

IDC

2

−/−

+ 3

12.8

5.4

NS

cT2-3 N1

Yes

NAT

THP-ddAC

PR

5 months

Remission

7

IDC

3

−/−

+ 3

23.3

5.3

HER2-E

cT2N0

na

na

Na

na

na

na

8

IDC

3

−/−

+ 3

20.7

6.4

NS

pT1cNx

Yes

AT

TH

N/A

27 months

Remission

9

ILC

2

−/−

+ 3

> 6

5.6

NS

pT1aN0

Yes

AT

TH

N/A

25 months

Remission

10

IDC

3

−/−

+ 3

26.3

7.6

HER2-E

pT1bN0

Yes

AT

TH

N/A

30 months

Remission

11

IDC

3

−/−

+ 3

> 10

> 3.8

HER2-E

pT1bN0

Yes

AT

TH

N/A

21 months

Remission

12

IMPC

3

−/−

+ 3

19.85

7.4

HER2-E

pT1cN1a

Yes

AT

ddAC-TH

N/A

28 months

Remission

13

IDC

2

+/−

+ 3

37.2

6.8

NS

pT1bN0

Yes

AT

ddAC-TH

N/A

26 months

Remission

14

IDC

3

+/−

+ 3

6.88

3.2

NS

pT2N1a

Yes

AT

THP ×12 weeks, ddACX2 (stopped 2/2 SAE, 1 year H)

N/A

22 months

Remission

15

IDC

3

+/−

+ 3

> 20

9.5

NS

pT1aN0

Yes

AT

T-DM1 on a trial

N/A

20 months

Remission

16

IDC

3

+/−

+ 3

23

8.1

HER2-E

pT1bN1a

Yes

AT

ddAC-THP

N/A

17 months

Remission

17

IDC

3

+/+

+ 3

> 10

3

NS

T2N1M1b

Yes

MET

THP, AC, various

N/A

35 months

Alive, on tx

18

IDC

3

−/−

+ 3

26.7

9.4

HER2-E

na

na

na

na

na

na

na

19

IDC

2

+/−

+ 3

20.3

3.4

NS

cT3N1

na

na

na

na

na

na

aHER2 IHC: 0–1+ is negative, 2+ is equivocal, 3+ is positive

bAll patients who received trastuzumab-based treatment received trastuzumab (H) for 1 year unless otherwise specified

cFollow up time defined as time in months from date of initial breast biopsy to date of last clinical follow-up

d HER2 ratio 1.0 because HER2 copies and CEP 17 copies both > 20, so HER2 alternative probe ratio performed to confirm HER2 status

AC Adriamycin + cyclophosphamide, AT adjuvant therapy, CR complete response, ddAC dose-dense adriamycin + cyclophosphamide, ER estrogen receptor, FISH fluorescence in-situ hybridization, H herceptin (trastuzumab), HER2 human epidermal growth factor receptor 2, HER2-E HER2-enriched, IDC invasive ductal cancer, IHC immunohistochemistry, ILC invasive lobular cancer, IMPC invasive micropapillary cancer, MET therapy for metastatic disease, N/A not applicable, na not available, NAT neoadjuvant therapy, NS not sufficient for testing, P pertuzumab, PR partial response, PR progesterone receptor, T weekly paclitaxel ×12, T-DM1 ado-trastuzumab, TNM tumor node metastasis, Tx therapy

Among the 31, alternative probe-positive cases, 30 (97%) were ER+ and 11 (35%) were high grade. In contrast, among the 19 cases that were HER2+ by traditional FISH criteria, nine (47%) were ER+ and 14 (74%) were high grade (p = 0.0002). Repeat HER2 testing was performed on a second tumor sample in 11 cases and seven of those were negative for HER2 gene amplification by both traditional FISH criteria and alternative probe method. Two cases were confirmed HER2+ by conventional FISH and two only by the alternative probe method (Tables 1 and 2).

Adequate tissue for PAM50 intrinsic subtype analysis was available for 20 alternative probe-positive cases and nine cases that were HER2+ by traditional FISH criteria. None (0%) of the 20 alternative probe cancers had HER2-enriched intrinsic subtype, while eight (89%) of the nine HER2+ traditional controls were of the HER2-enriched molecular subtype (p = 0.0001).

Clinical and pathologic data for patients in the alternative probe-positive cohort is provided in Table 1. Staging information was available for 24 patients. Twenty-one had early-stage disease (12 = node negative, 9 = node positive), one patient had a postmastectomy recurrence, and two patients had metastatic disease. Treatment information was available for 22 patients. Only four patients did not receive HER2-targeted therapy, one with metastatic disease and three with node-negative early-stage disease. Of the early stage patients who did receive HER2-targeted therapy, only two received it in the neoadjuvant setting, along with chemotherapy; one had a pathologic complete response (pCR) and one had partial responses (PR). Similarly, only four patients in the traditional HER2+ cohort received neoadjuvant HER2-targeted therapy with chemotherapy; two had a pathologic PR and two (both patients with HER2-enriched subtype) achieved pCR (Table 2). Given the small number of patients treated in the neoadjuvant setting, we cannot draw meaningful conclusions regarding response to HER2-targeted therapy among the alternative probe cases.

In the alternative probe-positive cohort, when considering the early-stage patients who received concurrent chemotherapy and HER2-targeted therapy, all except one had ER+ tumors, eight had no nodal involvement, and five had only N1a or N1mic disease. Had these tumors been considered HER2-negative, all might have been candidates for genomic expression assays to determine the need for chemotherapy, yet only three were evaluated for such (Table 1). Oncotype Dx was performed on tumors from three patients, with recurrence scores of 29, 26, and 12. The patient with the recurrence score of 12 had T1cN0 ER+ disease, was treated with endocrine therapy only without any chemotherapy or HER2-targeted therapy, and remains in remission at the last follow-up.

In conclusion, these findings highlight the unique pathologic and molecular characteristics of breast cancers classified as HER2+ only by an alternative probe method, and raise questions regarding the appropriate management of these cancers. More data regarding response of these breast cancers to HER2-targeted therapies is needed.

Notes

Declarations

Funding

Intrinsic subtype analysis was performed by CMP through the NCI Breast SPORE program (P50-CA58223), and by the Susan G. Komen (SAC-160074).

Availability of data and materials

All data generated and/or analyzed during this study are included in this published article.

Authors’ contributions

NVD contributed to the initial concept, protocol writing, IRB submission, data collection and interpretation, and manuscript writing. VT contributed to protocol writing, IRB submission, tissue acquisition, and submission and manuscript review. CC helped with protocol writing, submission to IRB, and data collection. JP, JTA, and GBR contributed to tissue processing and interpretation for intrinsic subtype analysis, and manuscript review. SJS contributed to the initial concept, protocol writing, IRB submission, tissue acquisition, and submission and manuscript review. CMP contributed to the concept, tissue processing and interpretation of intrinsic subtype analysis. NT contributed to the initial concept, protocol writing, IRB submission, interpretation of data, and manuscript review. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Dana-Farber/Harvard Cancer Center IRB. The IRB protocol number is DFCI Protocol No. 17–054.

Consent for publication

Not applicable.

Competing interests

CMP is an equity stock holder, consultant, and Board of Director Member of BioClassifier LLC. CMP is also listed as an inventor on patent applications on the Breast PAM50 Subtyping assay. The remaining authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Hematology-Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
(2)
Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, USA
(3)
Department of Genetics and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA
(4)
Department of Pathology and Laboratory Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, USA
(5)
Department of Pathology, Dana-Farber/Brigham and Women’s Cancer Center and Harvard Medical School, Boston, USA

References

  1. Figueroa-Magalhães MC, Jelovac D, Connolly R, et al. Treatment of HER2-positive breast cancer. Breast. 2014;23(2):128–36.View ArticlePubMedGoogle Scholar
  2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82.View ArticlePubMedGoogle Scholar
  3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.View ArticlePubMedGoogle Scholar
  4. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744–52.View ArticlePubMedPubMed CentralGoogle Scholar
  5. OA1 P, Guzman R, Cervantes M, Santiago A, Press MF. Characterization of HER2 status by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Methods Mol Biol. 1180(chapter 10):181–207.Google Scholar
  6. Prat A, Bianchini G, Thomas M, et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res. 2014;20:511e21.View ArticleGoogle Scholar
  7. Gnant M, Sestak I, Filipits M, et al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol. 2015;26(8):1685–9.View ArticlePubMedGoogle Scholar
  8. Cheang M, Martin M, Nielsn TO, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. Oncologist. 2015;20:474–82.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Prat A, Carey L, Adamo B, et al. Molecular features and survival outcomes of the intrinsic subtypes within Her2-positive breast cancer. J Natl Cancer Inst. 2014;106(8). PMID 25139534.Google Scholar
  10. Llombart-Cussac A, Cortes J, Pare L, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017;18(4):545–54. PMID: 28238593View ArticlePubMedGoogle Scholar
  11. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice guideline update. J Clin Oncol. 2013;31:3997–4013.View ArticlePubMedGoogle Scholar
  12. Tse CH, Hwang HC, Goldstein LC, et al. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2-targeted therapy. J Clin Oncol. 2011;29(31):4168–74.View ArticlePubMedGoogle Scholar
  13. Shah MV, Wiktor AE, Meyer RG, et al. Change in pattern of HER2 fluorescent in situ hybridization (FISH) results in breast cancers submitted for FISH testing: experience of a reference laboratory using US Food and Drug Administration criteria and American Society of Clinical Oncology and College of American Pathologists guidelines. J Clin Oncol. 2016;34(29):3502–10.View ArticlePubMedGoogle Scholar
  14. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement